Philippe Moreau, MD, on the Implications of Daratumumab Maintenance for Newly Diagnosed Multiple Myeloma

Video

Moreau discussed the implications of the second part of the CASSIOPEIA trial at the 2021 ASCO Annual Meeting.

CancerNetwork spoke with Philippe Moreau, MD, of the University Hospital of Nantes, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, regarding implications from part 2 of the phase 3 CASSIOPEIA trial (NCT02541383), which investigated daratumumab (Darzalex) maintenance following bortezomib, thalidomide, and dexamethasone (VTd) for patients with newly diagnosed multiple myeloma.

Transcription:

The main takeaway is that daratumumab maintenance is able to improve outcomes following stem cell transplantation, [although] this is restricted to patients who are not exposed as part of frontline treatment with a quadruplet [regimen] including daratumumab. We definitely need a longer follow-up to look at progression-free survival 2 [PFS2] and overall survival. When we evaluated PFS2, we also showed that there is a clear separation of the curves that is now occurring with a follow-up of 3 years; we definitely need a longer follow-up. The best PFS2 curve is the one for patients who received daratumumab up front and daratumumab maintenance, as well.

Reference

Moreau P & Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol. 2021;39(suppl 15):8004. doi:10.1200/JCO.2021.39.15_suppl.8004

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content